TABLE 3.
Baseline characteristics of 81 evaluable kidney transplant recipients with IFN-γ ELISpot at 1 month post-transplant <250 or ≥250 SFUs/2.5 × 105 PBMCs.
| Characteristics | IFN-γ ELISpot <250 SFUs/2.5 × 105 PBMCs N = 51 (%) | IFN-γ ELISpot ≥250 SFUs/2.5 × 105 PBMCs N = 30 (%) | p-value | Total (N = 81) |
|---|---|---|---|---|
| Female sex | 22 (43.1) | 12 (40.0) | 0.78 | 34 (42.0) |
| Age (years) | 45 ± 10 | 41 ± 11 | 0.07 | 44 ± 10 |
| Comorbidities | ||||
| Hypertension | 41 (80.4) | 25 (83.3) | 0.74 | 66 (81.5) |
| Diabetes mellitus | 9 (17.6) | 1 (3.3) | 0.08 | 10 (12.3) |
| Hyperparathyroidism | 17 (33.3) | 8 (26.7) | 0.53 | 27 (30.9) |
| Transplant type | 0.66 | |||
| DDKT | 38 (74.5) | 21 (70) | 59 (72.8) | |
| LRKT | 13 (25.5) | 9 (30) | 22 (27.2) | |
| BMI (kg/m2) | 22.6 ± 3.6 | 22.1 ± 3.7 | 0.6 | 22.4 ± 3.6 |
| CMV serostatus | 0.49 | |||
| D+/R+ | 49 (96) | 28 (93.4) | 77 (95.1) | |
| D−/R+ | 1 (2) | 1 (3.3) | 2 (2.5) | |
| D+/R− | 1 (2) | 0 (0) | 1 (1.2) | |
| Unknown donor CMV status/R+ | 0 (0) | 1 (3.3) | 1 (1.2) | |
| Re-transplantation | 3 (5.9) | 2 (6.7) | 1.0 | 5 (6.2) |
| HLA mismatch | 0.01 | |||
| 0 | 2 (3.9) | 7 (23.3) | 9 (11.1) | |
| 1–3 | 41 (80.4) | 22 (73.4) | 63 (77.8) | |
| 4–6 | 8 (15.7) | 1 (3.3) | 9 (11.1) | |
| PRA (%) | 0.43 | |||
| 0–10 | 38 (74.5) | 26 (86.6) | 64 (79) | |
| 11–50 | 6 (11.8) | 2 (6.7) | 8 (9.9) | |
| >50 | 7 (13.7) | 2 (6.7) | 9 (11.1) | |
| Induction therapy | 0.12 | |||
| Basiliximab | 35 (68.6) | 24 (80) | 59 (72.8) | |
| Anti-thymocyte globulin | 14 (27.5) | 3 (10) | 17 (21.0) | |
| None | 2 (3.9) | 3 (10) | 5 (6.2) | |
| Maintenance therapy | ||||
| Tacrolimus | 47 (92.2) | 30 (100) | 0.29 | 77 (95.1) |
| Cyclosporin | 4 (7.8) | 0 (0) | 0.29 | 4 (4.9) |
| Mycophenolate sodium | 13 (25.5) | 6 (20) | 0.57 | 19 (23.5) |
| Mycophenolate mofetil | 38 (74.5) | 24 (80) | 0.57 | 62 (76.5) |
| Prednisolone | 51 (100) | 30 (100) | NA | 81 (100) |
Abbreviations: IFN-γ ELISpot, enzyme-linked immunosorbent spot assay for interferon-gamma; SFUs, spot-forming units; PBMCs, peripheral blood mononuclear cells; DDKT, deceased-donor kidney transplantation; LRKT, living-related kidney transplantation; BMI, body mass index; CMV, cytomegalovirus; D, donor; R, recipient; +, seropositive; −, seronegative; HLA, human leukocyte antigen; PRA, panel-reactive antibody.
Bold value Indicates the significant p-value <0.05.